Black and white headshot of Amir Kalali, MD

Amir Kalali, MD

Executive Advisor for Global Strategy

Dr. Kalali helps identify innovative technologies to support the evolution of Signant’s growth. In addition, Dr. Kalali will assist in the acceleration of growth in Signant’s CNS product lines in other fields of medicine.  He is Professor of Psychiatry at University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development, published by Cambridge University Press. He has authored over 150 peer-reviewed publications. Recognized globally as a leader in drug development and healthcare with an emphasis on  innovation, collaboration, and the intersection with new technology, Dr. Kalali was the Founding Chairman of the Executive Committee of the International Society for CNS Drug Development  (ISCDD), a founding member of the International Society for CNS Clinical Trials and  Methodology (ISCTM), where he serves on Executive Committee, the Scientific Committee, and  previously chaired the Membership and Publication Committees. He is also a founder and Co- Chair of the Scientific Program Committee of the CNS Summit, and serves on the Scientific Program Committee of the American College of Neuropsychopharmacology. Dr. Kalali regularly presents at national and international scientific meetings, and lectures  frequently on drug development, innovation, technology, digital medicine and health.  He is an advisor to the Center for Digital Transformation at the Paul Merage School of Business  at the University of California, Irvine. Dr. Kalali earned his medical degree from the University of London and completed his psychiatry training at University College and Middlesex School of Medicine, University of London.